Announcements Trials

Browse Landscape

Phase

Status

Unknown 2 Terminated 1 Completed 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Esophageal Squamous Cell Carcinoma 2 Esophageal Neoplasms 2 Triple Negative Breast Neoplasms 1 Squamous Cell Carcinoma of Head and Neck 1 Nasopharyngeal Carcinoma 1 Mouth Neoplasms 1 Carcinoma, Non-Small-Cell Lung 1

Interventions

Carboplatin 341 Paclitaxel 262 Cisplatin 232 Pemetrexed 226 Docetaxel 206 Erlotinib Hydrochloride 193 Gemcitabine 178 pembrolizumab 136 Bevacizumab 121 Radiotherapy 118 Nivolumab 84 Gefitinib 72 Vinorelbine 64 Cetuximab 58 atezolizumab 47 Afatinib 46 durvalumab 44 osimertinib 41 Radiosurgery 35 Ipilimumab 34 Drug Therapy 32 Taxes 30 Albumin-Bound Paclitaxel 29 130-nm albumin-bound paclitaxel 29 Surgical Procedures, Operative 28 Etoposide 25 Irinotecan 24 Sorafenib 21 Cyclophosphamide 20 Radiation 19

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Completed × Carcinoma, Non-Small-Cell Lung × TP protocol × Clear all

NCT00680940 2012-08-07

NSCLC

Cadila Pharnmaceuticals

Phase 2 Completed

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon ⚡